Skip to main content

Novel Rx

      RT @doctorRBC: Extended 5 year study of secukinumab in AS patients showed sustained improvement of back pain, nocturnal

      Robert B Chao, MD doctorRBC

      4 years 10 months ago

      Extended 5 year study of secukinumab in AS patients showed sustained improvement of back pain, nocturnal back pain, AM stiffness, fatigue and LDA Abs#0364 @RheumNow #ACR20

      RT @uptoTate: The Great Debate results! https://t.co/tJk0yIRqfK

      Dr. Rachel Tate uptoTate

      4 years 10 months ago
      The Great Debate results! https://t.co/tJk0yIRqfK
      RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by BMS, @HorizonNews , @SanofiGenzyme,

      Dr. John Cush RheumNow

      4 years 10 months ago
      RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by BMS, @HorizonNews , @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
      RT @bella_mehta: How would you change csDMARDS and bDMARDS a few days before vaccination - if/when #COVID19 KILLED vacci

      Bella Mehta bella_mehta

      4 years 10 months ago

      How would you change csDMARDS and bDMARDS a few days before vaccination - if/when #COVID19 KILLED vaccine comes in (Assuming live vaccine would need strict medication management.) #ACR20 @RheumNow

      RT @drdavidliew: DVT/PE has been the sticking point for baricitinib in RA.

      DVT/PE risk in integrated safety analysis &g

      David Liew drdavidliew

      4 years 10 months ago
      DVT/PE has been the sticking point for baricitinib in RA. DVT/PE risk in integrated safety analysis >8y: incidence doesn't increase, but also doesn't decrease. No diff with dose either. Every drug has pros/cons; it's how we manage risk that counts... #ACR20 ABST0202 @RheumNow https://t.co/V88tQjcXSJ
      RT @RichardPAConway: Dr Fernandez-Diaz on abatacept in RA-ILD in 263 patients. Abatacept appears safe and effective. Equ

      Richard Conway RichardPAConway

      4 years 10 months ago
      Dr Fernandez-Diaz on abatacept in RA-ILD in 263 patients. Abatacept appears safe and effective. Equivalent to RTX. Good option as s/c admin @rheumnow #ACR20 Abstr#0233 #ACRbest https://t.co/LfjqZpnGCh
      Abatacept in RA and ILD Patients: Dr Richard Conway

      Dr. Richard Conway discusses abstract #0233 presented Friday at the 2020 ACR virtual annual meeting.

      Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.
      RT @KDAO2011: 4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6,
      cirrhosis NNH 1000
      5.LoDoCo2: colchicine p

      k dao KDAO2011

      4 years 10 months ago
      4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6, cirrhosis NNH 1000 5.LoDoCo2: colchicine prevents MACE: NNT 36 6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ: NNH 600
      RT @drpnash: Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Re

      Peter Nash drpnash

      4 years 10 months ago
      Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need
      RT @ACRheum: The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before b

      American College of Rheumatology ACRheum

      4 years 10 months ago
      The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06
      RT @ATSCPAssembly: Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo

      ATS Clinical Problems Assembly ATSCPAssembly

      4 years 10 months ago
      Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/
      Inadequate Response in Spondylitis: Dr. Olga Petryna

      Dr. Petryna discusses two abstracts being presented at the ACR 2020 meeting: #0359 and #0371

      QD Clinic - Running out of Options

      Difficult RA with Serious Infections and Limited options

      Axial Involvement in Psoriatic Arthritis: Dr. Eric Ruderman Perspective

      Dr. Eric Ruderman, Chicago, IL., provides his perspective on ACR 2020 coverage of axial involvement in Psoriatic Arthritis. During his remarks, he discusses ACR abstracts #0344, #1372, #2025 and #0505. 

      ×